Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure

Pharmacogenomics

Volumn 13, Issue 9, 2012, Pages 1087-1094

  Fransen, Jaap ^a   Kooloos, Wouter M ^b   Wessels, Judith A M ^b   Huizinga, Tom W J ^b   Guchelaar, Henk Jan ^b   Van Riel, Piet L C M ^a   Barrera, Pilar ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

effectiveness of therapy; methotrexate; pharmacogenetic models; prediction models; rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GENOMIC DNA; METHOTREXATE; PREDNISONE;

ADULT; AMPD1 GENE; ARTICLE; ATIC GENE; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; FEMALE; GENE; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; ITPA GENE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MTHFD1 GENE; PHARMACOGENETICS; PREDICTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AMP DEAMINASE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS, PHARMACOLOGICAL; FEMALE; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; INDIVIDUALIZED MEDICINE; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MIDDLE AGED; MULTIENZYME COMPLEXES; NUCLEOTIDE DEAMINASES; PYROPHOSPHATASES; TREATMENT OUTCOME;

EID: 84864416154     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.83     Document Type: Article

References (22)

1. Korpela M, Laasonen L, Hannonen P et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 50(7), 2072-2081 (2004).
2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146(6), 406-415 (2007).
3. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis. 68, 914-921 (2009).
4. Saunders SA, Capell HA, Stirling A. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 58(5), 1310-1317 (2008).
5. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
6. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54(4), 1063-1074 (2006).
7. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007).
8. Barrera P, van der Maas A, van Ede AE et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-a antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatol. (Oxford). 41(4), 430-439 (2002).
9. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43(1), 22-29 (2000).
10. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J. Rheumatol. Suppl. 69, 14-21 (2004).
11. Van der Heijde DM, van't Hof MA, van Riel PL et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann. Rheum. Dis. 49(11), 916-920 (1990).
12. Van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against rheumatism criteria. Arthritis Rheum. 39(1), 34-40 (1996).
13. Bleeker SE, Moll HA, Steyerberg EW et al. External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 56(9), 826-832 (2003).
14. Gricor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004).
15. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68, 1086-1093 (2009).
16. Bijlsma JW, Weinblatt ME. Optimal use of methotrexate: the advantages of tight control. Ann. Rheum. Dis. 66(11), 1409-1410 (2007).
17. Kapral T, Stamm T, Machold KP et al. Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure. Arthritis Res. Ther. 8(2), R46 (2006).
18. Visser K, Van der Heijde DM. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68, 1094-1099 (2009).
19. Van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann. Rheum. Dis. 66(10), 1356-1362 (2007).
20. Wessels JA, Kooloos WM, De Jonge R et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 54(9), 2830-2839 (2006).
21. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 361(9360), 865-872 (2003).
22. Spector TD, Ahmadi KR, Valdes AM. When is a replication not a replication? Or how to spot a good genetic association study. Arthritis Rheum. 54(4), 1051-1054 (2006).